PLENARY KEYNOTE SESSION
Monday, April 8 | 4:00pm
Leena Gandhi, MD, PhD,
Vice President, Immuno-Oncology Medical Development, Lilly Oncology
Dr. Gandhi graduated from the NYU School of Medicine and completed her residency at MGH, and fellowship at Dana-Farber Cancer Institute (DFCI) and MGH. She worked as a thoracic oncologist and phase I oncologist at DFCI and served as Director of Clinical Trials in the thoracic oncology program from 2013- 2016. She joined NYU Perlmutter Cancer Center as Associate Professor of Medicine and the Director of Thoracic Medical Oncology in 2016. She has worked on Phase 1, 2 and 3 trials of novel targeted therapies and immunotherapies in lung cancer, with a focus on evaluating potential biomarkers of response. She has been a lead investigator in clinical trials that helped define the use of PD-L1 as a biomarker of response to PD-1 inhibition in non-small cell lung cancer. Dr. Gandhi most recently served as the lead investigator on the KEYNOTE-189 study, establishing combination chemotherapy and immunotherapy a standard of care in initial treatment for most NSCLC. On June 25, 2018, Dr. Gandhi joined Lilly Oncology to lead immuno-oncology medical development.
* The program is subject to change without notice, due to unforeseen reason.